Trial Profile
A Phase 1, Open-label, Single-dose, Randomized, Crossover Study in Healthy Subjects of the Effects of Co-administration With Food on Exposure, and to Determine the Within-subject Variability in Exposure, to Relacorilant and Its Metabolites
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 May 2018
Price :
$35
*
At a glance
- Drugs Relacorilant (Primary)
- Indications Alcoholism; Cushing syndrome; Solid tumours
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
- 16 May 2018 Status changed from recruiting to completed.
- 27 Feb 2018 New trial record